New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
09:00 EDTOHRPOhr Pharmaceutical announces positive case report on Squalamine
Ohr Pharmaceutical announced that a case report on the first patient treated in an ongoing investigator sponsored trial with Squalamine eye drops in proliferative diabetic retinopathy was presented at the 37th Annual Macula Society Meeting, in Key Largo, Florida. Diabetic retinopathy is the second most common cause of vision loss. In PDR, abnormal blood vessels grow from the retina into the vitreous cavity of the eye, resulting in blindness if untreated. This ongoing 5 patient OHR-003 trial is designed to determine the efficacy of topical Squalamine Lactate Ophthalmic Solution, 0.2%, in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy. The endpoints include regression of neovascularization, anatomical measurements, visual acuity, and safety parameters.
News For OHRP From The Last 14 Days
Check below for free stories on OHRP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
17:26 EDTOHRPOhr Pharmaceutical reports Q3 EPS (9c), one estimate (10c)
Subscribe for More Information
August 13, 2014
08:35 EDTOHRPOhr Pharmaceutical announces additional phase II data from IMPACT study
Ohr Pharmaceutical announced additional interim data from the Phase II study evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration. The data demonstrated a visual acuity and anatomical benefit for the group of patients receiving the combination of OHR-102 and Lucentis PRN versus placebo eye drops plus Lucentis PRN. Jason Slakter, MD, Chief Medical Officer at Ohr, presented the data on Tuesday, August 12 at the 2014 Annual Meeting of the American Society of Retina Specialists. New data presented at ASRS showed that mean change in central subfield thickness was -139Ám in the OHR-102 arm versus -117Ám in the Lucentis monotherapy arm. Representative cases were shown at ASRS demonstrating that the combination of OHR-102 and Lucentis resulted in the resolution of sub-retinal hyper reflective material as well as intra-retinal and subretinal edema. There were no significant differences in the frequency of Lucentis PRN injections, which was the primary endpoint of the exploratory Phase II study. As announced previously, the mean number of Lucentis injections was 6.2 for the OHR-102 arm and 6.4 for the Lucentis monotherapy arm, which included the baseline injection and any injections required up to and including the final study visit for the interim analysis group. Squalamine eye drops were well tolerated and had a comparable safety profile to Lucentis monotherapy arm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use